Moody’s could cut Endo

Moody's Investors Service said it placed the ratings of Endo Luxembourg Finance I Co. Sarl and subsidiaries under review for downgrade, including the Ba3 corporate family rating, Ba3-PD probability of default rating, Baa3 senior secured rating and B1 senior unsecured rating.

At the same time, the agency affirmed the SGL-2 speculative grade liquidity rating, reflecting good liquidity prior to the acquisition of Par.

Moody's will evaluate Endo's liquidity based on its post-acquisition financing structure and the SGL may change as part of its analysis.

The review was prompted by Endo's announcement that it will acquire Par Pharmaceutical Holdings, Inc. for $8.05 billion in cash and equity. The acquisition will meaningfully increase financial leverage to a level that is well above Endo's target debt-to-EBITDA range of 3 times to 4 times.

Moody's estimates pro forma adjusted debt to EBITDA will be in the mid-5 times range at year-end 2015.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.